Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.32 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4799189 | 0.85 | MAPT (0.43) | ALDH1A1PDE10AKDM4ELMNAMAPT | |
| SCHEMBL4795744 | 0.85 | PDE7A (0.40) | KDM4ELMNAPOLBMEN1KMT2A | |
| SCHEMBL4798298 | 0.81 | CYP1A2 (0.31) | CYP3A4 | |
| SCHEMBL4798299 | 0.80 | ALDH1A1 (0.53) | ALDH1A1MAPTPOLBMEN1KMT2A | |
| SCHEMBL4797703 | 0.79 | ALDH1A1 (0.38) | ALDH1A1CASP1PDE10AKDM4ELMNA | |
| SCHEMBL2992329 | 0.77 | ALDH1A1 (0.52) | ALDH1A1CASP1PDE10AKDM4ELMNA | |
| SCHEMBL29764012 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CASP1PDE10AKDM4ELMNA | |
| SCHEMBL23850 | 0.77 | ALDH1A1 (0.50) | ALDH1A1CASP1PDE10AKDM4ELMNA | |
| SCHEMBL4800469 | 0.76 | SCN5A (0.40) | ALDH1A1PDE10AKDM4ELMNAMAPT | |
| SCHEMBL215985 | 0.76 | ERBB2 (0.50) | ALDH1A1KDM4EPOLBKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332493-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | OSI PHARMACEUTICALS (US) | 2008-02-19 | — | — | US | claimed |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-07-21 | — | — | US | claimed |
| US-6890924-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2005-05-10 | — | — | US | claimed |
| EP-1292591-B1 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2005-02-02 | — | — | EP | claimed |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER PRODUCTS INC. | 2002-11-14 | — | — | US | claimed |
| US-7332493-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | OSI PHARMACEUTICALS (US) | 2008-02-19 | — | — | US | disclosed |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-07-21 | — | — | US | disclosed |
| US-6890924-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1292591-B1 | SUBSTITUTED BICYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PROD INC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER PRODUCTS INC. | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169165-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | ALDH1A1 296/4885CASP1 238/4885PDE10A 1610/4885 |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | ALDH1A1 342/4885CASP1 118/4885PDE10A 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.